| # | Country | Total Patents | |
|---|---|---|---|
| #1 | EPO (European Patent Office) | 12 | |
| #2 | United States | 10 | |
| #3 | Hungary | 4 | |
| #4 | Japan | 4 | |
| #5 | Serbia | 4 | |
| #6 | China | 2 | |
| #7 | Australia | 1 | |
| #8 | WIPO (World Intellectual Property Organization) | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Medical technology | |
| #4 | Measurement |
| # | Technology | |
|---|---|---|
| #1 | Peptides | |
| #2 | Medical preparations | |
| #3 | Therapeutic chemical compounds | |
| #4 | Electrotherapy | |
| #5 | Analysing materials | |
| #6 | Microorganisms |
| # | Name | Total Patents |
|---|---|---|
| #1 | Hettmann Thore | 15 |
| #2 | Freeman Daniel J | 11 |
| #3 | Radinsky Robert | 11 |
| #4 | Rothe Mike | 11 |
| #5 | Treder Martin | 10 |
| #6 | Abraham Reimar | 9 |
| #7 | Borges Eric | 8 |
| #8 | Hartmann Susanne | 7 |
| #9 | Fukuchi Keisuke | 7 |
| #10 | Freeman Dan | 7 |
| Publication | Filing date | Title |
|---|---|---|
| WO2017137503A1 | Combination of human anti-fgfr4 antibody and sorafenib | |
| EP3180356A1 | Human anti-fgfr4 antibody | |
| EP3670539A1 | Material and methods for treating or preventing her-3 associated diseases | |
| AU2007324868A1 | Activated HER3 as a marker for predicting therapeutic efficacy |